Eli Lilly vs Merck (LLY vs MRK): The Pharma Showdown for 2026

Two of America's most important pharmaceutical companies, each sitting atop a multi-decade drug cycle. Lilly has GLP-1 obesity drugs — potentially the largest pharmaceutical market ever. Merck has Keytruda — the world's best-selling cancer drug. These are very different bets on very different healthcare trends.

Eli Lilly: The GLP-1 Opportunity

Tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for obesity — is generating the most excitement in the pharmaceutical industry in years. Clinical trials showed 15–25% body weight reduction in obese patients, outcomes previously seen only with bariatric surgery. The drug works by activating two gut hormone receptors simultaneously (GIP and GLP-1), making it more effective than earlier single-receptor GLP-1 drugs like Ozempic.

The addressable market is staggering. Roughly 40% of US adults qualify as obese. The global obesity market could reach $100B+ annually at peak. Lilly and its Danish competitor Novo Nordisk (Ozempic, Wegovy) are the dominant players in this race, and both are constrained primarily by manufacturing capacity — not demand. Lilly has invested billions in new manufacturing facilities to meet demand that is currently backlogged.

Lilly's pipeline extends well beyond GLP-1. It has a strong oncology pipeline, Alzheimer's drug donanemab (awaiting FDA approval), and immunology drugs. But the market is pricing LLY primarily on the GLP-1 opportunity — which means the stock is sensitive to any news that changes the GLP-1 narrative: competitor drugs, side effect data, insurance coverage decisions, or pricing policy changes.

Merck: The Keytruda Franchise and What Comes After

Keytruda (pembrolizumab) is the world's best-selling drug. It's approved for more than 20 types of cancer and is being tested in hundreds of additional clinical trials. Every new indication approval expands the market — oncologists prescribe it earlier in treatment lines, for more tumor types, and in combination with other therapies. The revenue runway is long.

The concern is the patent cliff. Keytruda's core US patents begin expiring around 2028, which means biosimilar competition will eventually arrive. Merck has been working on a subcutaneous (under-the-skin injection) formulation of Keytruda to extend exclusivity, and it has filed new patents around the formulation. But at some point, competition arrives — and Keytruda accounts for roughly 45% of Merck's revenue.

This is why Merck trades at a discount to its historical multiple and to LLY — the market is pricing in the Keytruda cliff risk. The contrarian argument: Merck's pipeline is stronger than the discount implies, Keytruda's subcutaneous formulation buys years, the animal health business provides stable earnings, and Gardasil remains a multi-billion-dollar vaccine franchise. If the market is over-penalizing the cliff, MRK is cheap.

Which Is the Better Buy?

LLY is a premium-priced bet on the GLP-1 market becoming as large as the bulls expect. At current valuations, a lot of good news is priced in. If manufacturing scales, insurance coverage expands, and the drug category grows as expected — LLY looks cheap today. If any part of that thesis disappoints, the stock has room to fall significantly from premium levels.

MRK is a value bet with a specific risk: the market overestimates the Keytruda patent cliff impact while underestimating the pipeline. At lower multiples, you're not paying much for Merck's pipeline optionality, which includes promising oncology drugs and new vaccine candidates. If the pipeline delivers, MRK re-rates.

For investors who want pharma exposure without concentration risk, owning both is the sensible approach — they cover different drug categories, different patient populations, and different near-term catalysts.

Frequently Asked Questions